← Back to Search

Pulmonary Surfactant

Lucinactant for Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Phase 2
Waitlist Available
Led By Yuh-Chin T Huang, MD, MHS
Research Sponsored by Windtree Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 30 days post initiation of dosing
Awards & highlights

Study Summary

This trial will test if a certain medication can improve the condition of patients with COVID-19 related acute lung injury.

Eligible Conditions
  • Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 30 days post initiation of dosing
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through 30 days post initiation of dosing for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
All-cause Mortality
Daily Lung Compliance (Static) on Ventilator
Days in the Hospital
+16 more

Side effects data

From 2022 Phase 2 trial • 20 Patients • NCT04389671
16%
Oxygen saturation decreased
11%
Pyrexia
11%
Sepsis
11%
Septic Shock
5%
Pneumonia staphylococcal
5%
Cardiac failure
5%
Hypertension
5%
Cardiac arrest
5%
Pneumonia pneumococcal
5%
Staphylococcal infection
5%
Acute kidney injury
5%
Pneumonia
5%
Pulmonary embolism
5%
Retching
5%
Hyperglycemia
5%
Hypernatraemia
5%
Hypomagnesaemia
5%
Hyponatraemia
5%
Hypophosphataemia
5%
Urinary retention
5%
Dysphonia
5%
Pulmonary mass
5%
Hypotension
5%
Thrombophlebitis superficial
5%
Pneumothorax
5%
Lung assist device therapy
5%
Eosinophilia
5%
Thrombocytopenia
5%
Bradycardia
5%
Bronchopulmonary aspergillosis
5%
Fungaemia
5%
Septic shock
5%
Blood gases abnormal
5%
Staphylococcus test positive
5%
Hypokalaemia
5%
Haemoptysis
5%
Hypercapnia
5%
Hypoxia
5%
Multiple organ dysfunction syndrome
5%
Bacteraemia
5%
COVID-19 pneumonia
5%
Surgical and medical procedures
5%
Deep vein thrombosis
5%
Atrial fibrillation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lyophilized Lucinactant

Trial Design

1Treatment groups
Experimental Treatment
Group I: Lyophilized LucinactantExperimental Treatment1 Intervention
Lyophilized Lucinactant reconstituted with sterile water for injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lucinactant
2007
Completed Phase 2
~190

Find a Location

Who is running the clinical trial?

Windtree TherapeuticsLead Sponsor
16 Previous Clinical Trials
1,444 Total Patients Enrolled
Yuh-Chin T Huang, MD, MHSPrincipal InvestigatorDuke University
Steve G Simonson, MDStudy DirectorWindtree Therapeutics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
2021. "The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04389671.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top